Background Image
Previous Page  131 / 156 Next Page
Information
Show Menu
Previous Page 131 / 156 Next Page
Page Background

129

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

57

Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med

2006; 20 Suppl 1: s3-s8.

58

Dale O, Piribauer M, Kaasa S, Moksnes K, Knobel H, Klepstad P. A double-blind, rando-

mized, crossover comparison between single-dose and double-dose immediate-release

oral morphine at bedtime in cancer patients. J Pain Symptom Manage 2009; 37(1): 68-76.

59

Darwish M, Kirby M, Jiang JG, Tracewell W, Robertson P, Jr. Bioequivalence following

buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects.

Clin Drug Investig 2008; 28(1): 1-7.

60

Darwish M, Kirby M, Robertson P, Jr., Tracewell W, Xie F. Dose proportionality of fentanyl

buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a ran-

domized, open-label, four-period, crossover, single-centre study. Clin Drug Investig 2010;

30(6): 365-373.

61

Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absorption of fentanyl from

fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin

Drug Investig 2007; 27(9): 605-611.

62

Davies A, Sitte T, Elsner F, Reale C, Espinosa J, Brooks D, Fallon M. Consistency of efficacy,

patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with

immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Mana-

ge 2011; 41(2): 358-366.

63

Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F, Radbruch L, Sjolund

KF, Stenberg M, Buchanan A. Multi-centre European study of breakthrough cancer pain:

pain characteristics and patient perceptions of current and potential management strate-

gies. Eur J Pain 2011; 15(7): 756-763.

64

De Conno F, Ripamonti C, Fagnoni E, Brunelli C, Luzzani M, Maltoni M, Arcuri E, Bertetto

O; MERITO Study Group. The MERITO Study: a multicentre trial of the analgesic effect

and tolerability of normal-release oral morphine during 'titration phase' in patients with

cancer pain. Palliat Med 2008; 22(3): 214-221.

65

De Pietri L, Siniscalchi A, Reggiani A, Masetti M, Begliomini B, Gazzi M, Gerunda GE, Pa-

setto A. The use of intrathecal morphine for postoperative pain relief after liver resection:

a comparison with epidural analgesia. Anesth Analg 2006; 102(4): 1157-1163.

66

Deegan CA, Murray D, Doran P, Ecimovic P, Moriarty DC, Buggy DJ. Effect of anaesthe-

tic technique on oestrogen receptor-negative breast cancer cell function in vitro. Br J

Anaesth 2009; 103(5): 685-690.

67

Deegan CA, Murray D, Doran P, Moriarty DC, Sessler DI, Mascha E, Kavanagh BP, Buggy

DJ. Anesthetic technique and the cytokine and matrix metalloproteinase response to

primary breast cancer surgery. Reg Anesth Pain Med 2010; 35(6): 490-495.

68

Dehghan R, Ramakrishnan J, Ahmed N, Harding R. The use of morphine to control pain

in advanced cancer: an investigation of clinical usage in Bangladesh. Palliat Med 2010;

24(7): 707-714.

69

Demmy TL, Nwogu C, Solan P, Yendamuri S, Wilding G, DeLeon O. Chest tube-delivered

bupivacaine improves pain and decreases opioid use after thoracoscopy. Ann Thorac Surg

2009; 87(4): 1040-1046.

Literaturverzeichnis